The purpose of this study is to compare the safety and effectiveness of giving HIV-infected
patients delavirdine (DLV) plus zidovudine (ZDV) plus 2 doses of indinavir (IDV) or ZDV plus
IDV plus lamivudine (3TC). This study also examines how the body processes DLV when it is
given in combination with other drugs.
In this multicenter, open-label study, 45 HIV-1-positive patients receive either combination
drug therapy with delavirdine (DLV), zidovudine (ZDV), and indinavir (IDV) or combination
drug therapy with ZDV, lamivudine (3TC), and IDV. NOTE: Patients are treated for 24 weeks
and may opt to continue on study for 24 additional weeks, if HIV-1 RNA is less than 5,000
copies/ml or at the investigator's discretion.
Patients must have:
- HIV-1 positive.
- CD4 count above 50.
- HIV-1 RNA greater than 20,000.
Less than 1 month prior treatment with zidovudine.
- Prior 3TC, protease inhibitors, or non-nucleoside reverse transcriptase inhibitors.
- Prior ZDV of greater than 1 month total duration.
- Protease inhibitors.
- Non-nucleoside reverse transcriptase inhibitors.